According to our recent payer coverage analysis for anemia treatments due to chronic kidney disease, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for anemia treatments due to chronic kidney disease shows that under the pharmacy benefit, more than 56% of the lives under commercial formularies are covered with utilization management restrictions.

Trends: In October 2018, UnitedHealthcare said that starting Jan. 1, 2019, it would require step therapy prior authorization for Part B covered items that are not preferred for new starts. The plan will prefer biosimilar Retacrit (epoetin alfaepbx) over Procrit (epoetin alfa) and Aranesp (darbepoetin alfa). Via AIS Health.